Selank 'feeling' videos: what the research actually supports

What did @jts.p3ps actually say?

The creator describes Selank as a peptide that modulates GABA and other brain pathways, then compares the subjective experience to "a very very light dose" of alprazolam, roughly 0.25 to 0.5 milligrams. They say the onset is "almost immediate" after subcutaneous injection and that the feeling is calm and collected without drowsiness or impaired control. They deliberately skip mechanism details and tell viewers to "do your own research."

That Xanax comparison is doing a lot of heavy lifting here. It anchors the audience's expectations around a well-known controlled substance, which colors how people will interpret and seek out this peptide. That framing deserves serious scrutiny, not just a nod.

Does the science back this up?

Partially, but the benzodiazepine comparison oversimplifies the mechanism in ways that matter. Selank is a synthetic heptapeptide derived from tuftsin, and the anxiolytic effects observed in animal and limited human studies do appear linked to GABAergic modulation, but the story is more complicated than "it's like a light Xanax."

A study by Semenova et al. (2010, Bulletin of Experimental Biology and Medicine) found that Selank produced anxiolytic effects in rodent models without the sedation, muscle relaxation, or tolerance development associated with classical benzodiazepines. A separate line of research (Zozulya et al., 2014, Drugs of the Future) noted Selank influences serotonin metabolism and brain-derived neurotrophic factor expression alongside GABAergic activity. That multi-target profile is precisely why the Xanax comparison is reductive. Benzodiazepines work primarily through allosteric GABA-A receptor potentiation. Selank appears to operate through a broader, less fully characterized set of pathways. Equating the two misleads anyone trying to understand the pharmacology or assess risk.

What did they get wrong (or right)?

Credit where it's due: the creator is right that Selank's subcutaneous onset is relatively fast, and right that the subjective experience differs from benzodiazepines in that sedation and disinhibition are not prominent features. Animal and early human data support a calming effect that does not appear to impair motor control the way benzos do. Those observations are consistent with the limited literature.

What they got wrong is using a milligram dose comparison to Xanax as a reference point at all. Alprazolam is a Schedule IV controlled substance with well-documented dependence liability. Framing Selank as functionally equivalent to a specific benzo dose, even a low one, sets up a misleading risk equivalence in the listener's mind. Selank has a different safety profile, different mechanism, and critically, almost no long-term human safety data. The creator also skips the fact that Selank is not FDA-approved and exists in a regulatory gray zone in the United States. Telling viewers to "do your own research" after a pharmacological comparison like that is not a responsible handoff.

What should you actually know?

Selank is not approved by the FDA for any medical use. Human clinical trial data is thin and largely comes from Russian research institutions, which have produced promising but not yet independently replicated findings. A clinical trial by Medvedev et al. (2014, Zhurnal Nevrologii i Psikhiatrii) reported reduced anxiety in patients with generalized anxiety disorder, but sample sizes were small and blinding quality has been questioned by outside reviewers.

The "almost immediate" subcutaneous onset claim is plausible given peptide pharmacokinetics but has not been rigorously timed in published human studies. Animal data supports rapid CNS penetration, but applying that directly to human subjective onset is an extrapolation.

• Selank is unscheduled in the US but is not approved for human therapeutic use by the FDA.
• The GABAergic comparison to alprazolam conflates two mechanistically distinct compounds.
• No long-term human safety studies exist for Selank at any dose.
• Sourcing and purity of peptides purchased outside a regulated medical framework are not guaranteed.

Bottom line

The creator's personal experience may be genuine, and some of the broad strokes about Selank's calming profile are supported by preclinical and limited clinical data. But comparing it to a specific milligram dose of a Schedule IV benzodiazepine without acknowledging the mechanistic differences or the near-total absence of long-term human safety data is a meaningful omission. Anyone considering Selank should have that conversation with a licensed clinician, not a TikTok comment section.